Scheduled for June 23 rd the CD19 Vaccine for cancer.

By backoffice, June 15, 2017

A small company located in Texas will release it’s findings and results
from 110 clinical trials on a treatment centered on a patients immune
system where the T cell will recognize and phagotize the cancer cell.
The release of their findings should lead to licensing fees that should
cause the price of the stock to explode.

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

Share your thoughts...

190 Comments on " Scheduled for June 23 rd the CD19 Vaccine for cancer."

Notify of
avatar

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Sophie
Guest
0

I am late to the party too, and thank you all for the research and comments. I think it is worth taking the risk. If wrong, may be a long term hold, but if right, nothing else can be better than this.

Ehren
Guest
0

It looks like you’re right. Bellicum is it. I just emailed them asking if you can invest directly with them. Hope to hear tomorrow. I’m new to this stuff, so need to ask a lot of basic questions!

John T
Guest
0

Did you get a reply on your question from them?

Judith Gebora
Guest
0

Dear Ehren, Can you please let me know what was the respond from them. Can invest directly with them? Thank you so much!
God beless you,

Ehren
Guest
0

No reply as yet. Still waiting.

ROBIN BARTHOLOMEW
Guest
0

Did you get a hold of the company what did they say

CIiveP
Guest
0
Good luck to all. My take on it – Bellicum may be “below the radar” because they are presenting stem cell transplant data and not focussing on patient survival as the trial goal however there are many analysts commenting on them they are not invisible and the consensus is that they are undervalued – the average analyst price is $28 Vs price today of c$12. I dont think the 23rd June is 100% guaranteed as a huge trigger – the abstracts for any meeting are published well in advance and I think it is unwise to assume every analyst has… Read more »
Add a Topic
5971
Charles
Guest
0

I am going to be really upset if we have been fed a bunch of hype by these financial advisors who are making a lot of money charging us for their findings, if you want to call it that. We should file a class action lawsuit against them. Today, BLCM is DOWN and that shouldn’t be. I think CliveP has given us a good analysis. What is going on?

Ron
Guest
0

The financial advisors don’t care about you or your investments. All they want is your money foe their reports.

Judith Gebora
Guest
0
Hello CliveP, From your article I did learn more then I could find out of this issue the last couple of days. Thank you. I almost invested a program, /which will relive the Texas company name and the stock name to buy – many specialist program pop up now/ luckily I didn’t have the $2500,- fee for it. Looks like to me you have a better knowledge and understanding of this process. I am really appreciate if can give me further information on this subject. Unfortunately my husband had a bladder cancer, /was removed the bladder/ and now came back… Read more »
Add a Topic
5971
Add a Topic
3397
CIiveP
Guest
0

Dear Judith, just seen your note – very sorry to hear about your husbands condition and god bless that he will recover in full and quickly

Judith Gebora
Guest
0

Thank you so much!

Sal
Guest
0

Look what was announced by Moleculin Biotech … MBRX

Sal
Guest
0

Moleculin Announces Significant Discovery with Potential to Treat Pancreatic Cancer
Metabolic Inhibitor Shows Greater Ability to Kill Pancreatic Cancer Cell Lines

Add a Topic
3397
Add a Topic
3397
Judith Gebora
Guest
0

JoHi Sal, Where was announced?

stevex
Guest
0
BLCM doesn’t seem to have it’s own cd19 trials. However, in 2016 it announced expanded collaboration with Ospedale Pediatrico Bambino Gesù (OPBG), a leading European pediatric research center and hospital. The OPBG collaboration is focused on preclinical and clinical development of CD19 and other CAR T and TCR therapeutics engineered with Bellicum’s CaspaCIDe® molecular safety switch technology. Their agreement is: The two organizations agreed to jointly develop CARs and other cell therapies discovered by OPBG and engineered with Bellicum’s CaspaCIDe safety switch, which is designed to reduce or eliminate cells that become toxic or are no longer needed. Under terms… Read more »
Add a Topic
5805
Add a Topic
5916
Add a Topic
5805
Judith Gebora
Guest
0

Thank you for the information!

stevex
Guest
0
Nov. 1, 2016– Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) and Ospedale Pediatrico Bambino Gesù (OPBG), a leading European pediatric research center and hospital, today announced that they have entered into an expanded collaboration focused on preclinical and clinical development of CD19 and other CAR T and TCR therapeutics engineered with Bellicum’s CaspaCIDe® molecular safety switch technology. The two organizations agreed to jointly develop CARs and other cell therapies discovered by OPBG and engineered with Bellicum’s CaspaCIDe safety switch, which is designed to reduce or eliminate cells that become toxic or are no longer needed. Under terms of this agreement, Bellicum agreed to… Read more »
Add a Topic
4668
Add a Topic
5805
Add a Topic
5916
stevex
Guest
0

Sorry for the double post with basically the same info. I wrote 2 because my post wasn’t showing up. I repeated with another and it didn’t show up either. I emailed customer service at 3:45 and didn’t get response until 10:30 and found both had finally posted. Good luck to all and especially Judith. Hope you find a cure to help.

Judith Gebora
Guest
0

Thank you Dear, we really need it!

ATHAR ALI
Member
24

your research is fantastic, it is little late but I found JUNO also in 2nd phase of CD-19 and T cell clinical trial. They are not from Texas and their description does not match the teaser.

Gary
Guest
0

I just got on board. Will soon get the drift of the discusion.

James
Guest
0

So is is BLCM that is going to explode in the stock market?

Add a Topic
5971
mich
Member
2

BLCM’s abstracts have already been released. There likely will be no surprises on 6/23. I’d be concerned about people selling on the news or lack of news. Buy now at your own risk.

stevex
Guest
0

Mich, you are probably right, but I hope not. I have bought some options on blcm but I used stops just in case.

Add a Topic
570
Judith Gebora
Guest
0

Stevex can I ask how you constructed and placed the option on this stock? I did bout the stock strait. Thank you!

Add a Topic
5971
Add a Topic
5971
stevex
Guest
0

Do you have a stock trading account? If so, you need to find out if you are approved for option trading. If all that is already set up I will be glad to help.

Add a Topic
5971
Judith Gebora
Guest
0

Dear Stevex, Yes I do have TradeKing/Ally account with level 3 for option trading. Before yesterday I bought 100 share of BLCM stock, which was up yesterday $112,- but today is down to $13,- profit. I don’t know how to put option on. I would like to sell /I think/ the stock, $1284,- is in stake. I am thank you for any help. My email is: jjg61752@aol.com Talk to you sun.

Add a Topic
5971
Add a Topic
5971
Judith Gebora
Guest
0

Hello Stevex, did you read my message? Thanks, waiting for your reply.

PeteB
Guest
0

Ospedale Pediatrico Bambino Gesù is a children’s hospital in Rome, so I assume the play is still on Bellicum

allen_6
Member
0

Hello, I have been trying to determine what the likely candidate is, but we seem to be all over the map on this one. Is it BLCM, or ZIOP, or PHMMF or PHM.MC, or BPTH, and finally OPBG. Are all these entities presenting at the 22nd Congress, or is it only BLCM?

Georges
Guest
0

Bellicum Pharmaceuticals Inc BLCM.

Add a Topic
4668
Judith Gebora
Guest
0

I would like to know it if anybody have answer and kind to share with us! Thank you,

stevex
Guest
0
John Weinberg Bellicum Pharmaceuticals Inc.,Houston,United States Speaker of (S146) BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) FACILITATES HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BOTH HEMATOLOGICAL MALIGNANCIES AND NON-MALIGNANT CONDITIONS Mattia Algeri (Ospedale Pediatrico Bambino Gesu,Rome,Italy) Friday 15:45 – 15:57 (P381) THE USE OF BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) TOGETHER WITH HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT TO TREAT CHILDREN WITH HEMOGLOBINOPATHIES AND ERYTHROID DISORDERS Alice Bertaina (Ospedale Pediatrico Bambino Gesu,Rome,Italy) Friday 17:15 – 18:45 (S495) IMPACT OF POST-TRANSPLANT INFUSION OF DONOR T CELLS GENETICALLY MODIFIED WITH INDUCIBLE CASPASE 9 SUICIDE GENE… Read more »
Add a Topic
4668
stevex
Guest
0
Annemarie Moseley Bellicum Pharmaceuticals Inc.,Houston,United States Speaker of (S146) BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) FACILITATES HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BOTH HEMATOLOGICAL MALIGNANCIES AND NON-MALIGNANT CONDITIONS Mattia Algeri (Ospedale Pediatrico Bambino Gesu,Rome,Italy) Friday 15:45 – 15:57 (P381) THE USE OF BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) TOGETHER WITH HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT TO TREAT CHILDREN WITH HEMOGLOBINOPATHIES AND ERYTHROID DISORDERS Alice Bertaina (Ospedale Pediatrico Bambino Gesu,Rome,Italy) Friday 17:15 – 18:45 (S495) IMPACT OF POST-TRANSPLANT INFUSION OF DONOR T CELLS GENETICALLY MODIFIED WITH INDUCIBLE CASPASE 9 SUICIDE GENE… Read more »
Add a Topic
4668
CIiveP
Guest
0
Its absolutely correct the abstracts are released – they were posted to the EHA website on 18th May. I read the abstract – it is one of the “Top 6” abstracts to be presented in the “presidential” session. . Even to a layman it is very impressive (they data relates to stem cell transplants) 1) About 70 non-malignants – 100% survival in stell cell transplant even if not a perfect match – not sure what the mortality would be normally but 100% clearly cant be beaten 2) About 40 malignants – approx 97 % survival 1 year later, spread across… Read more »
Add a Topic
3397
Add a Topic
5916
Add a Topic
3397
stevex
Guest
0
There are 7 presenters from OPG. All are talking about the same thing in association with Bellicum’s S146) BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) I will show just 1 of the presenters schedule followed by the list of opg speakers: Franco Locatelli Ospedale Pediatrico Bambino Gesu,Rome,Italy Speaker of (S146) BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) FACILITATES HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT IN CHILDREN WITH BOTH HEMATOLOGICAL MALIGNANCIES AND NON-MALIGNANT CONDITIONS Mattia Algeri (Ospedale Pediatrico Bambino Gesu,Rome,Italy) Friday 15:45 – 15:57 (P381) THE USE OF BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE… Read more »
Ehren
Guest
0

I got an answer from Moleculin. You need to go through a broker or open an online investing account. No direct there. Still haven’t heard from Bellicum.

stevex
Guest
0

In Bellicum’s profile it shows this:
It has a collaboration agreement with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesú for the design and development of various T cell immunotherapies

I went to the adaptimmune website and found a video quite similar to the one that is in the teaser adds.
This is the link if you would like to check i tout: (copy & paste)
http://www.adaptimmune.com/pipeline/pipeline-overview

bob
Guest
0

STEVEX, THANK YOU SO MUCH for your VERY DILIGENT WORK on ALL of this!! You and Clive are to be COMMENDED for the REAL research being done here on behalf of this group!! I agree that, PERHAPS, NOT a lot will happen tomorrow; then, again, maybe it will. In ANY case, GOOD LUCK TO ALL regarding a future purchase of Bellicum!! From a stock or, stock option perspective, Bellicum is STILL HIGHLY UNDERVALUED at this point in time.

Add a Topic
5971
Add a Topic
5971
derek hazelwood
Guest
0

i agree with all who have complimented these professional men who have endeavoured to caution us all and yet not discourage us by using intelligence
and common sense to create a calm and safe enviorment to discuss this really very important annoucement.so i am very grateful and sincere when i say i will turn my 1500 clients to this site and will continue to participate in their discusions.
farm phone 7054354

Charles
Guest
0

Baker Brothers Advisors LP hold over 5 million shares of BLCM, as of 3/31/2017, and Julian Baker is also involved in some manner with Alexion Pharmaceuticals’ buying which has been very active with sizeable buys June 14-15.

PeteB
Guest
0

Interesting enough… BLCM has gone up over a $1.40 as I write this and is currently trading at around $14.05 share.

Ed C
Guest
0

BLCM in after hours = $14.77. Friday should be fun. 2 presentations >3:45-4 and 5:15-6:45. Don’t know if 4:00 to 5:15 is a dinner break or other presentations??? These are Madrid times. Good luck everyone!!!

TerryK
Guest
0

what’s happening now? is it going to go back up from this pull back..you would think that a new discovery like this one would make it soar with little pull back..

Alan
Guest
0
My 8/18 15 dollar call options that I bought at the end of last week are up by 800%. I bought 15 of them for an average price of .37 cents. I just sold 5 yesterday at 1.50 (approx 400% gain) and got my initial money back and then some. Now I ride the other 10 contracts and see what happens. They closed st $2.45 today and the stock is up about another .65-.70 cents in after hours so the options will be up nicely in the morning from there and now hopefully good news and off the moon it… Read more »
Add a Topic
570
Add a Topic
5971
Add a Topic
570
William Scott
Guest
0

The BLCM company is across the highway from the University and close to the hospital where they do the testing if this helps

roy
Guest
0

what is the name of the company

Richard
Guest
0

Are you sure they don’t mean MBRX

stevex
Guest
0

Madrid Spain is + 7 hours in CD time zone. So that means 3:45 = 8:45 am Texas time

john
Guest
0

just interested…… Has anyone actually spent their money to gt the name direct from the “professionals”?

Judith Gebora
Guest
0

I don’t think so, because they offer the “professional” advise for $1997,- to $2497,- price!!! I learn more of this page, than any paid adviser.

john
Guest
0

My research shows Bellicum revenue for 2016…… £388,000.Therefore without paying the big bucks,this is too coincidental to ignore.

Ed C
Guest
0

Presentation info released on BLCM web site – “news release”

halathemet8@yahoo.com
Guest
0
halathemet8@yahoo.com

who is the Co for cd19

marcos
Guest
0

anybody knows the company name

ATHAR ALI
Member
24

As everybody talking, it looks like BLCM, but I have also bought some of JUNO and MBRX. JUNO is now in phase 2 clinical stage of CD19.

ronaroosky
Guest
0

With all the hype, Bellicum is DOWN this morning.

stevex
Guest
0

Have you heard of ‘buy the rumor, sell the news’ ? That is what is happening now as people are taking quick profits. It also presents a good buying chance if you are of the mind that the company is going to make bigger gains later.

Carol
Guest
0

Great research all. I’m new at this so hopefully, i’ll be able to do research like this sometime soon. I purchased BCLM on the hope that it might be the “next big thing” but unfortunately, it has been dropping this morning….

Alan
Guest
0
Being that you are new to trading I would suggest reading some trading books for beginners. Remember that the market is based on supply and demand. Also read and learn technical trading. Lookup stock charts.com and learn how to chart the stocks you are interested in so you can see where the stock has been and the historical price data. You will learn a lot about a stock from its chart. Nothing goes straight up and stocks have to correct to continue up. It’s actually very healthy. Some very basics to start with would be to watch your entry and… Read more »
Add a Topic
5971
Add a Topic
5971
Add a Topic
5971